Most stock screeners filter on price, volume, and technical indicators — data that every trader already sees. For event-driven traders focused on small-cap and biotech stocks, the meaningful screens are the ones that surface catalyst proximity, dilution risk scores, and filing signals: the information that creates the edge before price reflects it.
The major financial screening platforms — whether they're from brokerage firms, financial data providers, or third-party analytics companies — were built for a general investment audience. Their filters reflect what institutional investors screening for value or growth characteristics need. They are not designed to answer the questions event-driven small-cap traders actually ask:
These screens require data sources that generic screeners don't integrate: regulatory filing feeds, FDA catalyst calendars, government procurement databases, and corporate relationship mapping from material agreement exhibits.
Filtering by catalyst proximity — PDUFA dates, trial readout windows, contract renewal cycles — surfaces companies where a defined event is approaching within a specific timeframe. This is the starting point for most event-driven screens: not "what is trading technically well" but "what has a known event in the next 30-90 days."
For biotech traders, this means a screen that returns every company with a PDUFA date in the next 60 days, sorted by cash runway and dilution score, with links to the relevant regulatory filing that established the date. For contract traders, it means a screen on companies with expiring contracts in a specific agency or category.
A dilution risk screen filters the full coverage universe by severity score — returning companies with the most dangerous dilution profiles: large authorized-but-not-issued share counts, active ATM programs, toxic convertible structures, or upcoming warrant expirations. For traders who are short, this screen identifies the highest-risk dilution candidates. For traders who are long, it identifies the names to avoid regardless of the technical chart or fundamental thesis.
The dilution screen is most powerful when filtered by market cap: a dilution score of 70/100 in a $20M market cap company is existentially threatening; the same score in a $500M company with access to the capital markets is a manageable risk. See the full methodology for SEC filing research that underpins these scores.
Companies that suddenly increase their filing frequency are signaling something — either positive (new customer agreements, partnership disclosures, 8-K items announcing business developments) or negative (amendment after amendment to financing agreements, NT filings indicating disclosure problems). A screen on unusual filing velocity in the past 30 days surfaces names that deserve attention before the broader market notices the pattern.
Identifying which small-cap companies have undiscovered relationships with large-cap customers before those customers report earnings is a screening opportunity that requires relationship mapping data. A screen that returns every company with more than 15% revenue concentration in a customer reporting earnings next week creates a systematic opportunity pipeline that is invisible to traders relying on standard financial screeners.
The most effective screens combine multiple factors to surface high-conviction setups rather than a long list of candidates requiring individual evaluation. A well-constructed event-driven screen might look like:
That screen returns a small, actionable list of companies where a material event is approaching, the capital structure supports a clean entry, and there is sufficient trading volume to build and exit a position. Compare this to a standard screener that returns 500 results sorted by RSI or MACD crossover — the event-driven screen does the research work in the filter rather than after the list is returned.
Event-driven screens work as well for short setups as for long positions. A screen combining high dilution scores, upcoming shelf registration expirations, and NT filing history surfaces companies with elevated short-side risk. Adding a negative catalyst — a PDUFA date for a drug with weak historical analog approval rates, a major customer that has been reducing orders — increases conviction. The penny stock research tools guide covers the toxic convertible structure that creates the most reliable short setups in this category.
Standard screeners filter on price, volume, and technical indicators derived from historical trading data. Event-driven screeners filter on catalyst proximity (PDUFA dates, contract cycles, earnings windows), regulatory filing signals (new dilution events, material agreement disclosures), and proprietary risk scores derived from filing analysis. The difference is whether the screen surfaces what has already happened in the price or what is about to happen in the underlying business.
Catalyst proximity screens should be run at least weekly to capture companies entering the 30-60 day event window. Dilution risk screens are most useful on a daily or weekly basis during active market conditions. Filing velocity screens should be checked daily since unusual filing patterns can emerge quickly. Supply chain exposure screens should be refreshed ahead of each major earnings season — typically 2-3 weeks before the start of each reporting period.
No. Screening is for discovery — finding candidates you didn't know about. Position monitoring is for risk management — watching for material changes in companies you already own. Both are essential and serve different functions. The SEC filing alert system handles position monitoring by notifying you of changes in real time, while screeners run periodically to surface new opportunities.
A catalyst proximity screen requires: (1) a structured database of PDUFA dates, AdCom schedules, and clinical trial readout windows derived from regulatory filings and FDA calendar publications; (2) an association between these events and their publicly traded company identifiers; and (3) a filter mechanism that returns companies with events falling within a user-specified time window. This data is not available from standard financial data providers and requires purpose-built biotech intelligence platforms like BiotechSigns.
An effective dilution screen requires three underlying data points: shelf registration status (active S-3 with remaining capacity), warrant and convertible note overhang relative to float, and cash runway relative to the next likely financing need. A dilution severity score that synthesizes these three factors into a single number allows ranking across the coverage universe. DilutionWatch provides this score for 7,300+ tickers, updated in real time as new filings arrive.